News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Wednesday, August 24, 2022Pfizer Inc and BioNTech SE announced updated efficacy results from a Phase trial evaluating a three g dose series of the PfizerBioNTech COVID Vaccine
Translational Research Describes an Epigenetic Approach for Regulating Fear-Memory
Tuesday, August 23, 2022EpiVario Inc an emerging biotech company dedicated to developing innovative therapeutics for memoryrelated psychiatric disorders has announced significant preclinical research findings that have the potential to lead to a treatment approach for PostT...
Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT
Tuesday, August 23, 2022Vaderis Therapeutics AG a clinical stage biotechnology company specializing in treatments for rare diseases associated with vascular malformations has emerged from stealth mode and commenced its INSIGHT proofofconcept clinical trial This trial focuse...
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
Friday, August 19, 2022Jazz Pharmaceuticals plc announced it has initiated a new Phase trial to investigate the efficacy and safety of Epidiolex cannabidiol known as Epidyolex in Europe in children and adolescents with Epilepsy with MyoclonicAtonic Seizures EMAS The rando...
Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Friday, August 19, 2022Grnenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin RTX RTX is a highly potent Transient Receptor Potential Vanilloid TRPV agonist with a wellvalidated mechanism of...
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
Thursday, August 18, 2022RedHill Biopharma Ltd a specialty biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to RHB for the treatment of nontuberculous mycobacteria NTM disease following a positive opinion recommendati...
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
Thursday, August 18, 2022Aytu BioPharma Inc a pharmaceutical company focused on developing and commercializing novel therapeutics today announced that the US Patent and Trademark Office has issued a new patent No the patent for AREnzastaurin This patent titled Targeted Epi...
Bright Giant GmbH and Agilent Technologies Announce Collaboration: Innovation for Identification
Wednesday, August 17, 2022Bright Giant GmbH and Agilent Technologies are excited to announce their new product development collaboration designed to enhance nontargeted metabolomics workflows using AIbased methods and empower scientists to make novel impactful discoveries Thi...
AGAE's Pilot Plants Prove Rhamnolipid Production Breakthroughs
Wednesday, August 17, 2022AGAE Technologies LLC AGAE a specialty chemical and biotech company based in Corvallis Oregon USA is proud to announce that it is successfully operating the first fermentation and mass purification pilot plants in North America dedicated to producing...
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
Tuesday, August 16, 2022EpiAxis Therapeutics a leading epigenetics company with a focus on the treatment diagnosis and monitoring of cancer and the prevention of its recurrence and Peptilogics a biotech company engineering peptide therapeutics by combining computation and b...
